A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database

CNS Drugs

Volumn 30, Issue 7, 2016, Pages 647-654

  Chiappini, Stefania ^a   Schifano, Fabrizio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CANNABIS; GABAPENTIN; KETAMINE; OPIATE; PREGABALIN; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; DATA BASE; DRUG ABUSE; DRUG DEPENDENCE; DRUG FATALITY; DRUG MISUSE; EUROPEAN MEDICINES AGENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BEHAVIOR, ADDICTIVE; FACTUAL DATABASE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

ADULT; AMINES; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; CYCLOHEXANECARBOXYLIC ACIDS; DATABASES, FACTUAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PREGABALIN; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS;

EID: 84975144890     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0359-y     Document Type: Article

References (80)

1. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013;347:f6747.
2. Martinotti G, Lupi M, Sarchione F, et al. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19:6367–74.
3. Anonymous. Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012;21:152–4.
4. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6.
5. Corkery J, Claridge H, Loi B, et al. Drug-related deaths in the UK: annual report 2013. Drug-related deaths reported by Coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Police forces in Scotland; the Northern Ireland Statistics and Research Agency: annual report 2013 on deaths between January–December 2013. London: International Centre for Drug Policy, St George’s University of London. http://www.sgul.ac.uk/images/docs/idcp%20pdfs/National%20programme%20on%20substance%20abuse%20deaths/National_Programme_on_Substance_Abuse_Deaths-Annual_Report_2013_on_Drug-related_Deaths_in_the_UK_January-December_2012_PDF.pdf. Accessed 1 Oct 2015.
6. EMCDDA-Europol 2009. Annual report on the implementation of council decision 2005/387/JHA. http://www.emcdda.europa.eu/html.cfm/index132910EN.html. Accessed 1 Oct 2015.
7. Papazisis G, Tzachanis D. Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52:709–16.
8. Schifano F, Orsolini L, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14:15–26.
9. Piskorska B, Miziak B, Czuczwar SJ, et al. Safety issues around misuse of antiepileptics. Expert Opin Drug Saf. 2013;12:647–57.
10. Smith B, Higgins C, Baldacchino A, et al. Substance misuse of gabapentin. Br J Gen Pract. 2012;62:406–7.
11. Sweet AD. Pregabalin abuse and the risks associated for patients with a previous history of substance misuse. J Addict Res Ther. 2013;4:e116.
12. Millar, et al. Lyrica nights—recreational pregabalin abuse in an urban emergency department. Emerg Med J. 2013;30:874.
13. Kapil V, Green JL, LeLait MC, et al. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.
14. Schifano F, D’Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118–22.
15. Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012;11:487–502.
16. European Medicines Agency. European public assessment report (EPAR) for Lyrica-Pregabalin; 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000546/WC500046603.pdf. Accessed 16 Sep 2015.
17. Food and Drug Administration. Lyrica (pregabalin) prescribing information; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021446s013s014lbl.pdf. Accessed 1 Dec 2015.
18. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs. 2012;21:1019–29.
19. Drug Enforcement Administration. Drug scheduling, 2015. http://www.dea.gov/druginfo/ds.shtml. Accessed 16 Sep 2015.
20. MHRA. Drug analysis prints, 2015. http://www.mhra.gov.uk/drug-analysis-prints. Accessed 1 Dec 2015.
21. Caster O, Edwards I, Noren G, Lindquist M. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol. 2011;67:319–20.
22. Schwan S, Sundstrom A, Stjernberg E, et al. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous drug reaction reporting system. EurJ Clin Psychopharmacol. 2010;66:947–53.
23. Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70:197–204.
24. Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behaviour. Int J Clin Pharmacol Ther. 2013;51:441–2.
25. Yargic I, Alyanak Ozdemiroglu F. Pregabalin abuse: case report. Klinik Psikofarmakol Bülteni. 2011;21:64–6.
26. Kriikku, et al. Pregabalin serum levels in apprehended drivers. Forensic Sci Int. 2014;243:112–6.
27. Chalabianloo F, Schiott J. Pregabalin and abuse potential [review] [in Norwegian]. Tidsskr Nor Laegeforen. 2009;129:186–7.
28. Aldemir E, Altıntoprak AE, Coşkunol H. Pregabalin dependence: a case report. Turk Psikiyatri Derg. 2015;26:217–20.
29. Carrus D, Schifano F. Pregabalin misuse-related ıssues; ıntake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839–40.
30. Gahr M, Franke B, Freudenmann RW, et al. Concerns about pregabalin: further experience with its potential of causing addictive behaviours. J Addict Med. 2013;7:147–9.
31. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.
32. Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf. 2015;10:184–6.
33. Skopp G, Zimmer G. Pregabalin: a drug with abuse potential? [Article in German]. Arch Kriminol. 2012;229:44–54.
34. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ. 2013;347:f7339.
35. Howland RH. Gabapentin for substance use disorders: is it safe and appropriate? J Psychosoc Nurs Ment Health Serv. 2014;6:1–4.
36. Mobasher M, Ziaaddini H, Sabzvari F, Sadeghipour S. The effect of gabapentin on withdrawal syndrome, psychiatric disorders and electroencephalogram of opium addicts during the detoxification period. Iran J Pharm Res. 2010;4:215–23.
37. Sanders NC, Manino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013;21:294–302.
38. Ziaaddini H, Ziaaddini A, Asghari N, et al. Trial of tramadol plus gabapentin for opioid detoxification. Iran Red Crescent Med J. 2015;17:e18202.
39. Howland RH. Gabapentin: can it be misused? J Psychosoc Nurs Ment Health Serv. 2014;52:12–5.
40. Markowitz JS, Finkenbine R, Myrick H, et al. Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol. 1997;17:423–4.
41. Reccoppa L, Malcom R, Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict. 2004;13:321–3.
42. MHRA 2015. Drug analysis print; gabapentin. http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_8473480656172106.pdf. Accessed 14 May 2016.
43. Mah L, Hart M. Gabapentin withdrawal: case report in an older adult and review of the literature. J Am Geriatr Soc. 2013;61:1635–7.
44. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28:835–54.
45. Badgaiyan RD. A novel perspective on dopaminergic processing of human addiction. J Alcohol Drug Depend. 2013;1.
46. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain. 2009;146:26–33.
47. Brawek B, Loffler M, Dooley DJ, et al. Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:301–7.
48. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–9.
49. EudraVigilance. European Medicines Agency, 2015. https://eudravigilance.ema.europa.eu/human/index.asp. Accessed 1 Oct 2015.
50. Gov.uk. Countries in the EU and EEA. https://www.gov.uk/eu-eea. Accessed 5 Mar 2016.
51. Heads of Medicines Agency (HMA) and European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module VI: management and reporting of adverse reactions to medicinal products 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf. Accessed 1 Dec 2015.
52. Medical Dictionary for Adverse Drug Reactions. MedDRA Version 18.0 English March 2015. http://www.meddra.org/how-to-use/support-documentation/english. Accessed 5 Nov 2015.
53. MedDRA Term Selection: points to consider. Release 4.9 Based on MedDRA Version 18.0 March 2015. http://www.meddra.org/how-to-use/support-documentation/english. Accessed 23 Mar 2016.
54. WHO Expert Committee on Addiction-Producing Drugs. Thirteenth report of the WHO Expert Committee: WHO Technical Report Series, No. 273. Geneva: World Health Organization, 1964.
55. European Medicines Agency. Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system, 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdf. Accessed 9 Mar 2016.
56. WHO. The WHO Programme for International Drug Monitoring. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/. Accessed 27 Nov 2015.
57. Felicetti P, Trotta F, Bonetto C, et al; Brighton Collaboration Vasculitis Working Group. Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases. Vaccine. 2015. doi:10.1016/j.vaccine.2015.09.027.
58. Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;63:1335–42.
59. Lowry F. Gabapentin new drug of abuse? Medscape Medical News; December 11, 2015. http://www.medscape.com/viewarticle/855819. Accessed 16 Dec 2015.
60. Nichter B, Chassin L. Separate dimensions of anxiety differentially predict alcohol use among male juvenile offenders. Addict Behav. 2015;50:144–8.
61. Foster DW, Buckner JD, Schmidt NB, Zvolensky MJ. Multisubstance use among treatment-seeking smokers: synergistic effects of coping motives for cannabis and alcohol use and social anxiety/depressive symptoms. Subst Use Misuse. 2016;51:165–78.
62. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? Int J Risk Saf Med. 2013;25:155–68.
63. Fernández-Suárez E, Villa-Estébanez R, Garcia-Martinez A, et al. Prevalence, type of epilepsy and use of antiepileptic drugs in primary care. Rev Neurol. 2015;60:535–42.
64. Schiltenwolf M, Pogatzki-Zahn EM. Pain medicine from intercultural and gender-related perspectives. Schmerz. 2015;29:569–75.
65. O’Donnell S, Vanderloo S, McRae L, et al. Comparison of the estimated prevalence of mood and/or anxiety disorders in Canada between self-report and administrative data. Epidemiol Psychiatr Sci. 2015;17:1–10.
66. Lourenço S, Costa L, Rodrigues AM, et al. Gender and psychosocial context as determinants of fibromyalgia symptoms (fibromyalgia research criteria) in young adults from the general population. Rheumatol (Oxford). 2015;54:1806–15.
67. Szentkiralyi A, Fendrich K, Hoffmann W, et al. Socio-economic risk factors for incident restless legs syndrome in the general population. J Sleep Res. 2012;21:561–8.
68. Finocchi C, Strada L. Sex-related differences in migraine. Neurol Sci. 2014;35(Suppl 1):207–13.
69. Ojanperä I, Kriikku P, Vuori E. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. Int J Legal Med. 2016. [Epub ahead of print].
70. Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010;123:367–73.
71. Wills B, Reynolds P, Chu E, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10:254–60.
72. Hakkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.
73. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657–9.
74. Pitkala KH, Juola AL, Hosia H, et al. Eight-year trends in the use of opioids, other analgesics, and psychotropic medications among institutionalized older people in Finland. J Am Med Dir Assoc. 2015;16:973–8.
75. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115–8.
76. Loftus H, Wright A. Potential misuse of pregabalin and gabapentin. BMJ. 2014;348:g1290.
77. Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24:173–7.
78. Reeves EE, Ladner ME. Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine. Am J Psychiatry. 2014;171:691.
79. Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–5.
80. Bicknell M. The pain of pregabalin prescribing in prisons. Br J Gen Pract. 2013;63:405.